Imricor lodges updated ASX corporate governance statement for 2025

The latest announcement is out from Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ).

Imricor Medical Systems has lodged its latest corporate governance statement with the ASX for the financial year ended 31 December 2025, confirming the document is current as of 27 March 2026 and approved by the board. The filing, accompanied by an Appendix 4G, outlines Imricor’s adoption of ASX Corporate Governance Council principles, including board charters, director vetting, written agreements for executives and directors, and board accountability structures, underscoring its efforts to align governance practices with market expectations for listed companies.

By providing a detailed key to where its governance disclosures are located and affirming compliance with core recommendations, Imricor enhances transparency for investors and regulators. This structured approach is intended to help stakeholders assess the robustness of the company’s oversight frameworks and verify that it is meeting the disclosure and governance standards expected of ASX-listed issuers.

The most recent analyst rating on (AU:IMR) stock is a Sell with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

Imricor Medical Systems, Inc. is a medical technology company focused on developing and supplying devices and systems for cardiac procedures. The company is listed on the ASX via CHESS Depositary Interests and operates under Australian corporate governance requirements for listed entities.

Average Trading Volume: 296,890

Technical Sentiment Signal: Buy

Current Market Cap: A$622.6M

For an in-depth examination of IMR stock, go to TipRanks’ Overview page.